Errata (DOI:10.1053/j.ajkd.2009.05.011);Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled Trial

American Journal of Kidney Diseases

Volumn 54, Issue 3, 2009, Pages 459-467

  Akizawa, Tadao ^a   Asano, Yasushi ^b   Morita, Satoshi ^c   Wakita, Takafumi ^d,e   Onishi, Yoshihiro ^d   Fukuhara, Shunichi ^c   Gejyo, Fumitake ^f   Matsuo, Seiichi ^g   Yorioka, Noriaki ^h   Kurokawa, Kiyoshi ⁱ  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Japanese Red Cross Koga Hospital   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d Institute for Health Outcomes and Process Evaluation Research   (Japan)

^e KANSAI UNIVERSITY   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HIROSHIMA UNIVERSITY   (Japan)

ⁱ NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

Author keywords

carbonaceous oral adsorbent; chronic kidney disease (CKD); Randomized controlled trial

Indexed keywords

AST 120;

ADULT; ARTICLE; BLOATING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; DRUG EFFECT; EVENT FREE SURVIVAL; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 68849123039     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.020     Document Type: Erratum

References (20)

1. Nakagawa N., Hasebe N., Sumitomo K., et al. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 26 (2006) 455-461
2. Taki K., and Niwa T. Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease. J Ren Nutr 17 (2007) 48-52
3. Shimoishi K., Anraku M., Kitamura K., et al. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 24 (2007) 1283-1289
4. Kobayashi N., Maeda A., Horikoshi S., Shirato I., Tomino Y., and Ise M. Effects of oral adsorbent AST-120 (Kremezin) on renal function and glomerular injury in early-stage renal failure of subtotal nephrectomized rats. Nephron 91 (2002) 480-485
5. Okada K., Okawa E., Shibahara H., et al. Combination therapy with angiotensin-converting enzyme inhibitor and oral adsorbent of uremic toxins can delay the appearance of glomerular sclerosis and interstitial fibrosis in established renal failure. Kidney Blood Press Res 27 (2004) 218-225
6. Okada K., Matsumoto K., and Takahashi S. Uremic toxins adsorbed by AST-120 promote tubular hypertrophy and interstitial fibrosis in nephrectomized rats. Kidney Blood Press Res 28 (2005) 8-13
7. Imai E., Takenaka M., Isaka Y., et al. Carbonic adsorbent AST-120 retards progression of renal failure by additive effect with ACEI and protein restriction diet. Clin Exp Nephrol 7 (2003) 113-119
8. Koide K., Sano M., Takeda F., Momose T., Koshikawa S., and Akizawa T. A study of oral adsorbent in chronic renal failure. Biomater Artif Cells Immobilization Biotechnol 19 (1991) 147-166
9. Shoji T., Wada A., Inoue K., et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 105 (2007) c99-c107
10. Sanaka T., Fujimoto K., Niwayama J., et al. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF. Am J Kidney Dis 41 suppl 1 (2003) S35-S37
11. Takahashi N., Kawaguchi T., and Suzuki T. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: Two-year study [erratum in Int J Urol 13:98, 2006]. Int J Urol 12 (2005) 7-11
12. Schulman G., Agarwal R., Acharya M., Berl T., Blumenthal S., and Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47 (2006) 565-577
13. Ueda H., Shibahara N., Takagi S., Inoue T., and Katsuoka Y. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 11 (2007) 189-195
14. Kang H.Y., Cho W., Lee S., Kim H.J., Lee H.Y., and Woo T.W. [Estimating the cost savings due to the effect of Kremezin in delaying the initiation of dialysis treatments among patients with chronic renal failure] [in Korean]. J Prev Med Public Health 39 (2006) 149-158
15. Yorioka N., Kiribayashi K., Naito T., et al. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease. J Nephrol 21 (2008) 213-220
16. Morita S., Fukuhara S., Akizawa T., Asano Y., and Kurokawa K. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol 9 (2005) 219-227
17. Horio M., Orita Y., Manabe S., Sakata M., and Fukunaga M. Formula and nomogram for predicting creatinine clearance from serum creatinine concentration. Clin Exp Nephrol 1 (1997) 110-114
18. Matsuo S., Imai E., Horio M., et al. Revised equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. Am J Kidney Dis 53 (2009) 982-992
19. Akizawa T., Koide K., and Koshikawa S. Effects of Kremezin on patients with chronic renal failure: Results of a nationwide clinical study (in Japanese). Kidney Dial 45 (1998) 373-388
20. Pocock S.J., and Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975) 103-115